You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 196101 - 196110 of 207725 results
  1. TOPIC 210 SOC MARKET TO DISSEM EVID-BSD ENERGY BAL INTERV APPROACHES TO WRKSITES

    SBC: DANYA INTERNATIONAL, INC.            Topic: N/A

    N/A

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC 210 SOC MARKET TO DISSEM EVID-BSD ENERGY BAL INTERV APPROACHES TO WRKSITES

    SBC: ISA ASSOCIATES INC            Topic: N/A

    N/A

    SBIR Phase I 2005 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 454- SOFTWARE TO EVALUATE ARTIFICIAL INTELLIGENCE/MACHINE LEARNING MEDICAL DEVICES IN ONCOLOGY SETTINGS

    SBC: GRADIENT HEALTH, INC.            Topic: 454

    Supervised, Machine Learning based oncologic AI algorithms degrade over time and don’t generalize well. The FDA requires the conduct of standalone testing of radiologic, AI products to characterize their performance. Sourcing representative data with sufficient variability is time consuming, expensive, and often under-represent the variety of image quality experienced in clinical reality. FDA Re ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 454- SOFTWARE TO EVALUATE ARTIFICIAL INTELLIGENCE/MACHINE LEARNING MEDICAL DEVICES IN ONCOLOGY SETTINGS

    SBC: CARINA MEDICAL LLC            Topic: 454

    Artificial intelligence (AI)-based software devices are starting to play key roles in healthcare with more and more regulatory approval and clinical adoptions. Segmentation is a key task in oncology settings including radiation treatment planning and volumetric assessment to assist cancer diagnosis and treatment monitoring. In radiation oncology, multiple AI segmentation devices have obtained FDA ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Topic 2 Subtopic a Title: Accelerated Deployment of MFEM Based Solvers in Large Scale Industrial Problems

    SBC: RELOGIC RESEARCH, INC.            Topic: C5302a

    While many Advanced Scientific Computing Research (ASCR) supported software packages are open source, they are often complicated to use, distributed primarily in source-code form targeting HPC systems, and potential adopters lack options for purchasing commercial support, training, and custom- development services. In response to this need, ReLogic Research, Inc., in collaboration with Lawrence Li ...

    SBIR Phase I 2022 Department of Energy
  6. TOPIC 385: SURVIVORCARE: A DIGITAL HEALTH SOLUTION TO SUPPORT LONG-TERM CANCER SURVIVORSHIP USING PATIENT NAVIGATION- MOONSHOT

    SBC: DIMAGI, INC.            Topic: NCI

    The overall objective of this Phase I SBIR project is to study the feasibility and acceptability of SurvivorCarea mobileand web based system to support long term cancer survivorship through patient navigation for low incomeunderserved populationsFollowing a user centered design approachthe contractor will develop a tool expressly designed for patient navigatorsPNsand colorectal cancer survivors to ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Topic 374: Sustained Delivery of PARP Inhibitors for Cancer Chemoprevention

    SBC: TheraNano LLC            Topic: NCI

    Here we propose to study two injectable formulations that provide different delivery routes for Talazoparib, potent PAPR inhibitor: An implant, InCeT-Talazoparib, which can be injected directly in the tumor where it will act as a sustained release depot of Talazoparib over a prolonged period of approximately 30 days. It delivers 100% of the drug to the tumor site with almost no systemic toxicity. ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Topic 377: Symptom Management and Intervention Roadmaps (STaIRS)

    SBC: CAREVIVE SYSTEMS INC            Topic: NCI

    Numerous adverse symptoms are under-detected in cancer care resulting1-3 in missed opportunities for intervention; leading to poor treatment adherence, avoidable hospitalizations, and worse morbidity and survival. The IOM proposed shaking up the current symptom paradigm from reactive to proactive, personalized, technology-enabled models of symptom care as a solution to this clinical quality crisis ...

    SBIR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC 377: SYMPTOM MANAGEMENT AND INTERVENTION ROADMAPS (STAIRS) (MOONSHOT) PHASE II

    SBC: CAREVIVE SYSTEMS INC            Topic: 377

    Numerous adverse symptoms are under-detected in cancer care resulting1-3 in missed opportunities for intervention; leading to poor treatment adherence, avoidable hospitalizations, and worse morbidity and survival. The IOM proposed shaking up the current symptom paradigm from reactive to proactive, personalized, technology-enabled models of symptom care as a solution to this clinical quality crisis ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  10. TOPIC 414: SYNTHETIC BIOLOGY GENE CIRCUITS FOR CANCER THERAPY

    SBC: Strand Therapeutics Inc.            Topic: 414

    B-cell non-Hodgkin’s lymphoma (NHL) is the most common hematological malignancy derived from B-cells and expresses high levels of the CD19 antigen. Although past gene therapy efforts that target CD19, such as chimeric antigen T cell receptor (CAR-T) immunotherapy, have demonstrated immense clinical benefit, manufacturing challenges and toxicity have significantly limited its utility. To this end ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government